Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril ...
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the U.S. Food and Drug Administration (FDA) has ...
A medication that could help treat early stages of Alzheimer's disease is on track to be approved for manufacturing and sales in Japan after being endorsed by a health ministry expert panel on Aug. 21 ...
At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed ...
An interim analysis from the ALZ-NET registry found that lecanemab's real-world safety profile in Alzheimer's patients closely mirrors clinical trial results, with no new safety concerns identified.
STOCKHOLM, March 23, 2026 /PRNewswire/ -- BioArctic's AB (publ) (NASDAQ: BIOA B) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and ...
Early real-world safety data from the ALZ-NET registry show lecanemab’s side effect profile aligns with clinical trial findings, with no new safety concerns. The registry, launched in 2022, tracks ...
A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.
STOCKHOLM, March 11, 2026 /PRNewswire/ -- BioArctic's AB (publ) (STOCKHOLM: BIOA B) partner Eisai announced today that they will present the latest findings on lecanemab at the 2026 International ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results